Human MutL homolog 1 immunoexpression in oral leukoplakia and oral squamous cell carcinoma: A prospective study in Indian population

Background: Mammalian mismatch repair system is responsible for maintaining genomic stability during repeated duplications, and human MutL homolog 1 (hMLH1) protein constitutes an important part of it. Various isolated studies have reported the altered expression of hMLH1 in oral leukoplakia (OL) an...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of oral and maxillofacial pathology : JOMFP 2016-09, Vol.20 (3), p.453-461
Hauptverfasser: Chaudhari, Narendra, Tupkari, Jagdish, Joy, Tabita, Ahire, Manisha
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 461
container_issue 3
container_start_page 453
container_title Journal of oral and maxillofacial pathology : JOMFP
container_volume 20
creator Chaudhari, Narendra
Tupkari, Jagdish
Joy, Tabita
Ahire, Manisha
description Background: Mammalian mismatch repair system is responsible for maintaining genomic stability during repeated duplications, and human MutL homolog 1 (hMLH1) protein constitutes an important part of it. Various isolated studies have reported the altered expression of hMLH1 in oral leukoplakia (OL) and oral squamous cell carcinoma (OSCC). Research is lacking in the quantitative estimation and comparison of hMLH1 expression in OL and OSCC. Aims: To evaluate, quantify and compare hMLH1 immunoexpression in normal oral mucosa, OL and OSCC. Settings and Design: Thirty patients of OL and thirty patients of OSCC formed the study group and thirty patients were included in the control group (normal oral mucosa). Formalin-fixed paraffin wax blocks were prepared from the tissue samples. Materials and Methods: Immunohistochemistry for hMLH1 was performed, and the total number of positive cells was counted in high-power fields, and based on that percentage positivity of hMLH1 was calculated in all the cases. Statistical Analysis: Kruskal-Wallis and t-test were used. P < 0.05 was considered to be statistically significant. Results: The mean hMLH1 value in control group, leukoplakia and OSCC was 78.26, 54.33 and 40.97 respectively. hMLH1 immunoexpression showed decreasing indexes from control group to leukoplakia and then further to OSCC. hMLH1 expression was significantly lower in OSCC as compared to leukoplakia. There was no significant correlation of mean hMLH1 expression between different clinical and histopathological stages of leukoplakia and OSCC. Conclusions: hMLH1 immunoexpression was inversely related to the degree of dysplasia. These findings suggest that there is a progressive decrease in hMLH1 expression from control to leukoplakia and further to OSCC. Thus, it can be concluded that hMLH1 can be used as a reliable biomarker for malignant transformation.
doi_str_mv 10.4103/0973-029X.190948
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5051294</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A464206492</galeid><sourcerecordid>A464206492</sourcerecordid><originalsourceid>FETCH-LOGICAL-c486x-24dd7b6016420358b3d19a9062db7f65cd93b220c2a6247d0a55d9813cf024ff3</originalsourceid><addsrcrecordid>eNptks1v0zAYhyMEYmVw54QsceGS4q98mANSNQGbVMQFxG6WazudV8fO7Hjd7vzhOLQrK0I-RLJ_7-O8r5-ieI3gnCJI3kPWkBJidjlHDDLaPilmiLG2JIxcPi1mh-OT4kWM1xBWLa3w8-IENw1GNUKz4td56oUDX9O4BFe-99avAQKm75Pz-m4IOkbjHTAO-CAssDpt_GDFxgggnNptxpskep8ikNpaIEWQxvlefAALMAQfBy1Hc6tBHJO6n0gXTpl85-CHZMWY8S-LZ52wUb_af0-LH58_fT87L5ffvlycLZalpG19V2KqVLOqIaophqRqV0QhJhissVo1XV1JxcgKYyixqDFtFBRVpViLiOwgpl1HTouPO-6QVr1WUrsx_z8fgulFuOdeGH584swVX_tbXsEKYUYz4N0eEPxN0nHkvYlT18LpPACOWlKR_BIE5-jbf6LXPgWX25tSbUPqBtd_U2thNTeu8_leOUH5gk5t1pRNrPl_Unkp3Rvpne5M3j8qgLsCmecfg-4OPSLIJ3P4pAaf1OA7c3LJm8ezORQ8qJIDP3eBrbejDnFj01YHnrMb57dH4PIRmNOK8D-S8UkyvpeMI_4gGfkNkSHdDg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1838736726</pqid></control><display><type>article</type><title>Human MutL homolog 1 immunoexpression in oral leukoplakia and oral squamous cell carcinoma: A prospective study in Indian population</title><source>PubMed Central Open Access</source><source>Medknow Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Chaudhari, Narendra ; Tupkari, Jagdish ; Joy, Tabita ; Ahire, Manisha</creator><creatorcontrib>Chaudhari, Narendra ; Tupkari, Jagdish ; Joy, Tabita ; Ahire, Manisha</creatorcontrib><description>Background: Mammalian mismatch repair system is responsible for maintaining genomic stability during repeated duplications, and human MutL homolog 1 (hMLH1) protein constitutes an important part of it. Various isolated studies have reported the altered expression of hMLH1 in oral leukoplakia (OL) and oral squamous cell carcinoma (OSCC). Research is lacking in the quantitative estimation and comparison of hMLH1 expression in OL and OSCC. Aims: To evaluate, quantify and compare hMLH1 immunoexpression in normal oral mucosa, OL and OSCC. Settings and Design: Thirty patients of OL and thirty patients of OSCC formed the study group and thirty patients were included in the control group (normal oral mucosa). Formalin-fixed paraffin wax blocks were prepared from the tissue samples. Materials and Methods: Immunohistochemistry for hMLH1 was performed, and the total number of positive cells was counted in high-power fields, and based on that percentage positivity of hMLH1 was calculated in all the cases. Statistical Analysis: Kruskal-Wallis and t-test were used. P &lt; 0.05 was considered to be statistically significant. Results: The mean hMLH1 value in control group, leukoplakia and OSCC was 78.26, 54.33 and 40.97 respectively. hMLH1 immunoexpression showed decreasing indexes from control group to leukoplakia and then further to OSCC. hMLH1 expression was significantly lower in OSCC as compared to leukoplakia. There was no significant correlation of mean hMLH1 expression between different clinical and histopathological stages of leukoplakia and OSCC. Conclusions: hMLH1 immunoexpression was inversely related to the degree of dysplasia. These findings suggest that there is a progressive decrease in hMLH1 expression from control to leukoplakia and further to OSCC. Thus, it can be concluded that hMLH1 can be used as a reliable biomarker for malignant transformation.</description><identifier>ISSN: 0973-029X</identifier><identifier>EISSN: 1998-393X</identifier><identifier>DOI: 10.4103/0973-029X.190948</identifier><identifier>PMID: 27721611</identifier><language>eng</language><publisher>India: Wolters Kluwer - Medknow Publications</publisher><subject>Development and progression ; Gene expression ; Genetic aspects ; Health aspects ; Mouth cancer ; Original ; Properties ; Squamous cell carcinoma ; Tumor proteins</subject><ispartof>Journal of oral and maxillofacial pathology : JOMFP, 2016-09, Vol.20 (3), p.453-461</ispartof><rights>COPYRIGHT 2016 Medknow Publications and Media Pvt. Ltd.</rights><rights>Copyright Medknow Publications &amp; Media Pvt Ltd Sep-Dec 2016</rights><rights>Copyright: © Journal of Oral and Maxillofacial Pathology 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c486x-24dd7b6016420358b3d19a9062db7f65cd93b220c2a6247d0a55d9813cf024ff3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5051294/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5051294/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27458,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27721611$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chaudhari, Narendra</creatorcontrib><creatorcontrib>Tupkari, Jagdish</creatorcontrib><creatorcontrib>Joy, Tabita</creatorcontrib><creatorcontrib>Ahire, Manisha</creatorcontrib><title>Human MutL homolog 1 immunoexpression in oral leukoplakia and oral squamous cell carcinoma: A prospective study in Indian population</title><title>Journal of oral and maxillofacial pathology : JOMFP</title><addtitle>J Oral Maxillofac Pathol</addtitle><description>Background: Mammalian mismatch repair system is responsible for maintaining genomic stability during repeated duplications, and human MutL homolog 1 (hMLH1) protein constitutes an important part of it. Various isolated studies have reported the altered expression of hMLH1 in oral leukoplakia (OL) and oral squamous cell carcinoma (OSCC). Research is lacking in the quantitative estimation and comparison of hMLH1 expression in OL and OSCC. Aims: To evaluate, quantify and compare hMLH1 immunoexpression in normal oral mucosa, OL and OSCC. Settings and Design: Thirty patients of OL and thirty patients of OSCC formed the study group and thirty patients were included in the control group (normal oral mucosa). Formalin-fixed paraffin wax blocks were prepared from the tissue samples. Materials and Methods: Immunohistochemistry for hMLH1 was performed, and the total number of positive cells was counted in high-power fields, and based on that percentage positivity of hMLH1 was calculated in all the cases. Statistical Analysis: Kruskal-Wallis and t-test were used. P &lt; 0.05 was considered to be statistically significant. Results: The mean hMLH1 value in control group, leukoplakia and OSCC was 78.26, 54.33 and 40.97 respectively. hMLH1 immunoexpression showed decreasing indexes from control group to leukoplakia and then further to OSCC. hMLH1 expression was significantly lower in OSCC as compared to leukoplakia. There was no significant correlation of mean hMLH1 expression between different clinical and histopathological stages of leukoplakia and OSCC. Conclusions: hMLH1 immunoexpression was inversely related to the degree of dysplasia. These findings suggest that there is a progressive decrease in hMLH1 expression from control to leukoplakia and further to OSCC. Thus, it can be concluded that hMLH1 can be used as a reliable biomarker for malignant transformation.</description><subject>Development and progression</subject><subject>Gene expression</subject><subject>Genetic aspects</subject><subject>Health aspects</subject><subject>Mouth cancer</subject><subject>Original</subject><subject>Properties</subject><subject>Squamous cell carcinoma</subject><subject>Tumor proteins</subject><issn>0973-029X</issn><issn>1998-393X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptks1v0zAYhyMEYmVw54QsceGS4q98mANSNQGbVMQFxG6WazudV8fO7Hjd7vzhOLQrK0I-RLJ_7-O8r5-ieI3gnCJI3kPWkBJidjlHDDLaPilmiLG2JIxcPi1mh-OT4kWM1xBWLa3w8-IENw1GNUKz4td56oUDX9O4BFe-99avAQKm75Pz-m4IOkbjHTAO-CAssDpt_GDFxgggnNptxpskep8ikNpaIEWQxvlefAALMAQfBy1Hc6tBHJO6n0gXTpl85-CHZMWY8S-LZ52wUb_af0-LH58_fT87L5ffvlycLZalpG19V2KqVLOqIaophqRqV0QhJhissVo1XV1JxcgKYyixqDFtFBRVpViLiOwgpl1HTouPO-6QVr1WUrsx_z8fgulFuOdeGH584swVX_tbXsEKYUYz4N0eEPxN0nHkvYlT18LpPACOWlKR_BIE5-jbf6LXPgWX25tSbUPqBtd_U2thNTeu8_leOUH5gk5t1pRNrPl_Unkp3Rvpne5M3j8qgLsCmecfg-4OPSLIJ3P4pAaf1OA7c3LJm8ezORQ8qJIDP3eBrbejDnFj01YHnrMb57dH4PIRmNOK8D-S8UkyvpeMI_4gGfkNkSHdDg</recordid><startdate>20160901</startdate><enddate>20160901</enddate><creator>Chaudhari, Narendra</creator><creator>Tupkari, Jagdish</creator><creator>Joy, Tabita</creator><creator>Ahire, Manisha</creator><general>Wolters Kluwer - Medknow Publications</general><general>Medknow Publications and Media Pvt. Ltd</general><general>Medknow Publications &amp; Media Pvt. Ltd</general><general>Medknow Publications &amp; Media Pvt Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160901</creationdate><title>Human MutL homolog 1 immunoexpression in oral leukoplakia and oral squamous cell carcinoma: A prospective study in Indian population</title><author>Chaudhari, Narendra ; Tupkari, Jagdish ; Joy, Tabita ; Ahire, Manisha</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c486x-24dd7b6016420358b3d19a9062db7f65cd93b220c2a6247d0a55d9813cf024ff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Development and progression</topic><topic>Gene expression</topic><topic>Genetic aspects</topic><topic>Health aspects</topic><topic>Mouth cancer</topic><topic>Original</topic><topic>Properties</topic><topic>Squamous cell carcinoma</topic><topic>Tumor proteins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chaudhari, Narendra</creatorcontrib><creatorcontrib>Tupkari, Jagdish</creatorcontrib><creatorcontrib>Joy, Tabita</creatorcontrib><creatorcontrib>Ahire, Manisha</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of oral and maxillofacial pathology : JOMFP</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chaudhari, Narendra</au><au>Tupkari, Jagdish</au><au>Joy, Tabita</au><au>Ahire, Manisha</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Human MutL homolog 1 immunoexpression in oral leukoplakia and oral squamous cell carcinoma: A prospective study in Indian population</atitle><jtitle>Journal of oral and maxillofacial pathology : JOMFP</jtitle><addtitle>J Oral Maxillofac Pathol</addtitle><date>2016-09-01</date><risdate>2016</risdate><volume>20</volume><issue>3</issue><spage>453</spage><epage>461</epage><pages>453-461</pages><issn>0973-029X</issn><eissn>1998-393X</eissn><abstract>Background: Mammalian mismatch repair system is responsible for maintaining genomic stability during repeated duplications, and human MutL homolog 1 (hMLH1) protein constitutes an important part of it. Various isolated studies have reported the altered expression of hMLH1 in oral leukoplakia (OL) and oral squamous cell carcinoma (OSCC). Research is lacking in the quantitative estimation and comparison of hMLH1 expression in OL and OSCC. Aims: To evaluate, quantify and compare hMLH1 immunoexpression in normal oral mucosa, OL and OSCC. Settings and Design: Thirty patients of OL and thirty patients of OSCC formed the study group and thirty patients were included in the control group (normal oral mucosa). Formalin-fixed paraffin wax blocks were prepared from the tissue samples. Materials and Methods: Immunohistochemistry for hMLH1 was performed, and the total number of positive cells was counted in high-power fields, and based on that percentage positivity of hMLH1 was calculated in all the cases. Statistical Analysis: Kruskal-Wallis and t-test were used. P &lt; 0.05 was considered to be statistically significant. Results: The mean hMLH1 value in control group, leukoplakia and OSCC was 78.26, 54.33 and 40.97 respectively. hMLH1 immunoexpression showed decreasing indexes from control group to leukoplakia and then further to OSCC. hMLH1 expression was significantly lower in OSCC as compared to leukoplakia. There was no significant correlation of mean hMLH1 expression between different clinical and histopathological stages of leukoplakia and OSCC. Conclusions: hMLH1 immunoexpression was inversely related to the degree of dysplasia. These findings suggest that there is a progressive decrease in hMLH1 expression from control to leukoplakia and further to OSCC. Thus, it can be concluded that hMLH1 can be used as a reliable biomarker for malignant transformation.</abstract><cop>India</cop><pub>Wolters Kluwer - Medknow Publications</pub><pmid>27721611</pmid><doi>10.4103/0973-029X.190948</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0973-029X
ispartof Journal of oral and maxillofacial pathology : JOMFP, 2016-09, Vol.20 (3), p.453-461
issn 0973-029X
1998-393X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5051294
source PubMed Central Open Access; Medknow Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Development and progression
Gene expression
Genetic aspects
Health aspects
Mouth cancer
Original
Properties
Squamous cell carcinoma
Tumor proteins
title Human MutL homolog 1 immunoexpression in oral leukoplakia and oral squamous cell carcinoma: A prospective study in Indian population
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T14%3A32%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Human%20MutL%20homolog%201%20immunoexpression%20in%20oral%20leukoplakia%20and%20oral%20squamous%20cell%20carcinoma:%20A%20prospective%20study%20in%20Indian%20population&rft.jtitle=Journal%20of%20oral%20and%20maxillofacial%20pathology%20:%20JOMFP&rft.au=Chaudhari,%20Narendra&rft.date=2016-09-01&rft.volume=20&rft.issue=3&rft.spage=453&rft.epage=461&rft.pages=453-461&rft.issn=0973-029X&rft.eissn=1998-393X&rft_id=info:doi/10.4103/0973-029X.190948&rft_dat=%3Cgale_pubme%3EA464206492%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1838736726&rft_id=info:pmid/27721611&rft_galeid=A464206492&rfr_iscdi=true